Jubilant Pharmova Limited
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.
What Jubilant files
- Others59
- Updates41
- Important23
- Investor Meet16
- Board Meeting13
- Dividend/Bonus4
Jubilant Pharmova Limited has informed the Exchange about General Updates
Jubilant Pharmova received a GST demand notice for Rs. 87.31 Cr (tax, interest, penalty) for FY2022-23. The company disputes the claim, calling it incorrect, and expects no financial or operational impact, planning a detailed reply.
Jubilant Generics (subsidiary) received a Show Cause Notice for alleged inadmissible IGST refund, demanding Rs. 52.75 Cr GST and Rs. 52.75 Cr penalty plus interest. The company contests this, stating it's incorrect and expects no financial impact.
Jubilant Pharmova secured USFDA approval for commercial batch manufacturing on Line 3 at its Spokane, USA contract facility. This green light for the new isolator-based fill and finish line boosts capacity and operational readiness, signaling enhanced business potential.
Jubilant Pharmova's Q1 FY27 revenue grew 17% to Rs 2,229 Cr. EBITDA fell 11% to Rs 268 Cr due to SPECT product issues & Montreal costs. SPECT production resumes; H2 FY27 recovery expected. CDMO Line 3 ramps up, Line 4 installed, US$60M+ PET expansion underway.